TROP2-specific second-generation CAR-T cells

Stages

1. 1.
   CAR design and cell product generation(library_build)

   This stage creates the engineered T-cell product needed for downstream efficacy and safety testing.

   Selection: Construct a TROP2-targeting second-generation CAR based on Sacituzumab and express it in primary human T cells.

2. 2.
   In vitro functional screening against TNBC cell lines(broad_screen)

   This stage establishes whether the engineered T cells have measurable antitumor function against TNBC targets before in vivo evaluation.

   Selection: Assess tumor cytotoxicity, cytokine production, and T-cell proliferation against multiple TNBC cell lines.

3. 3.
   In vivo efficacy testing in xenograft and PDX models(confirmatory_validation)

   This stage confirms that in vitro activity translates to antitumor efficacy in animal models, including orthotopic, metastatic, and patient-derived settings.

   Selection: Evaluate antitumor efficacy in orthotopic and metastatic cell line-derived xenograft models in NSG mice and in a PDX model.

4. 4.
   Safety assessment in TROP2-humanized immunocompetent mice(in_vivo_validation)

   This stage tests whether antitumor activity can be achieved without damaging normal tissues that express TROP2.

   Selection: Assess safety profile in a TROP2-humanized immunocompetent mouse model.

5. 5.
   Logic-gated redesign to mitigate toxicity(library_design)

   This redesign stage addresses the safety failure of the direct TROP2 CAR-T approach while aiming to retain efficacy.

   Selection: Engineer a B7-H3/TROP2 AND-logic gated SynNotch CAR to minimize off-tumor on-target toxicity.

6. 6.
   Comparative validation of gated CAR-T design(confirmatory_validation)

   This stage tests whether the logic-gated redesign solves the key safety problem without sacrificing antitumor function.

   Selection: Compare antitumor efficacy and apparent adverse effects of the B7-H3/TROP2 SynNotch CAR-T design against the direct TROP2 CAR-T design.

Steps

1. 1.
   Construct TROP2-targeting second-generation CAR from Sacituzumab-based binderengineered cell therapy construct

   Create a TROP2-directed CAR design for TNBC targeting.

   A defined CAR construct is required before expression in T cells and downstream functional testing.

2. 2.
   Express TROP2 CAR in primary human T cells using retroviral vectorengineered cell product

   Generate TROP2 CAR-T cells for preclinical testing.

   The CAR must be introduced into primary human T cells before in vitro and in vivo evaluation.

3. 3.
   Test cytotoxicity, cytokine production, and proliferation against multiple TNBC cell linescell therapy being screened

   Measure core in vitro antitumor functions of TROP2 CAR-T cells.

   In vitro assays provide an initial functional readout before more resource-intensive animal studies.

4. 4.
   Evaluate antitumor efficacy in orthotopic and metastatic NSG xenograft models and PDXcell therapy being validated

   Confirm in vivo antitumor efficacy across multiple TNBC model formats.

   Animal efficacy testing follows in vitro activity to assess whether tumor control extends to more complex in vivo settings.

5. 5.
   Assess safety of TROP2 CAR-T cells in TROP2-humanized immunocompetent micecell therapy being safety-tested

   Detect on-target off-tumor toxicity in a model intended to reveal normal-tissue liabilities.

   Safety testing is needed after efficacy is established to determine whether the direct TROP2-targeting strategy is translationally viable.

6. 6.
   Engineer B7-H3/TROP2 AND-logic gated SynNotch CAR-T cellsredesigned gated cell therapy construct

   Reduce off-tumor on-target toxicity while maintaining antitumor activity.

   This redesign follows the safety failure of direct TROP2 CAR-T cells and is intended to improve selectivity.

7. 7.
   Compare efficacy and apparent adverse effects of gated SynNotch CAR-T cells versus direct TROP2 CAR-T cellscomparator and redesigned therapy formats

   Determine whether the gated design resolves the key safety problem without sacrificing efficacy.

   A direct comparison is needed after redesign to justify the gated approach as a viable solution.